Aerovate Therapeutics (AVTE) Short Interest Ratio & Short Volume $7.90 -0.18 (-2.23%) As of 08/29/2025 Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aerovate Therapeutics Short Interest DataAerovate Therapeutics (AVTE) has a short interest of 4.59 million shares, representing 21.72% of the float (the number of shares available for trading by the public). This marks a 6.99% increase in short interest from the previous month. The short interest ratio (days to cover) is 18.1, indicating that it would take 18.1 days of the average trading volume of 12,438 shares to cover all short positions.Current Short Interest4,590,000 sharesPrevious Short Interest4,290,000 sharesChange Vs. Previous Month+6.99%Dollar Volume Sold Short$12.35 millionShort Interest Ratio18.1 Days to CoverLast Record DateApril 15, 2025Outstanding Shares28,985,000 sharesFloat Size21,130,000 sharesShort Percent of Float21.72%Today's Trading Volume47,960 sharesAverage Trading Volume12,438 sharesToday's Volume Vs. Average386% Short Selling Aerovate Therapeutics? Sign up to receive the latest short interest report for Aerovate Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAVTE Short Interest Over TimeAVTE Days to Cover Over TimeAVTE Percentage of Float Shorted Over Time Aerovate Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20254,590,000 shares $12.35 million +7.0%21.7%18.1 $2.69 3/31/20254,290,000 shares $10.77 million -0.5%20.3%30.4 $2.51 3/15/20254,310,000 shares $10.65 million -0.5%20.5%27.7 $2.47 2/28/20254,330,000 shares $10.52 million +5.1%20.6%25.1 $2.43 2/15/20254,120,000 shares $10.09 million +2.5%19.6%22.1 $2.45 1/31/20254,020,000 shares $10.53 million +6.9%20.5%18.1 $2.62 1/15/20253,760,000 shares $9.25 million +49.2%19.2%4.9 $2.46 12/31/20242,520,000 shares $6.68 million +35.5%12.9%3.3 $2.65 12/15/20241,860,000 shares $4.71 million +3.9%9.5%2.4 $2.53 11/30/20241,790,000 shares $4.71 million -5.3%9.1%2.3 $2.63 Get the Latest News and Ratings for AVTE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/20241,890,000 shares $4.78 million +243.8%9.7%2.5 $2.53 10/31/2024549,800 shares $1.35 million -17.3%2.8%0.7 $2.45 10/15/2024665,000 shares $1.40 million -21.4%3.4%2.8 $2.11 9/30/2024846,500 shares $1.77 million -20.9%4.3%3 $2.09 9/15/20241,070,000 shares $2.03 million -15.8%5.5%2 $1.90 8/31/20241,270,000 shares $2.45 million +9.5%6.5%1.1 $1.93 8/15/20241,160,000 shares $2.08 million +23.5%5.9%1 $1.79 7/31/2024939,000 shares $1.71 million +11.4%4.9%0.8 $1.82 7/15/2024842,600 shares $1.60 million -6.4%4.4%0.8 $1.90 6/30/2024900,400 shares $1.49 million -57.7%4.7%0.8 $1.66 6/15/20242,130,000 shares $52.44 million -3.6%11.1%2.3 $24.62 5/31/20242,210,000 shares $38.56 million +0.9%11.7%10.7 $17.45 5/15/20242,190,000 shares $46.01 million +16.5%12.0%13.1 $21.01 4/30/20241,880,000 shares $37.62 million +50.4%10.4%13.1 $20.01 4/15/20241,250,000 shares $31.63 million +25.9%7.2%8.3 $25.30 3/31/2024993,100 shares $29.37 million +9.9%5.8%7.6 $29.57 3/15/2024903,700 shares $24.13 million -10.5%5.3%8.8 $26.70 2/29/20241,010,000 shares $23.31 million -9.8%5.9%10.7 $23.08 2/15/20241,120,000 shares $24.24 million +5.7%6.6%11.7 $21.64 1/31/20241,060,000 shares $20.47 million +11.3%6.2%11.8 $19.31 1/15/2024952,100 shares $19.13 million -0.8%5.6%12.6 $20.09 12/31/2023959,300 shares $21.71 million -12.0%5.6%11.7 $22.63 12/15/20231,090,000 shares $19.62 million -10.7%6.4%13.2 $18.00 11/30/20231,220,000 shares $19.17 million -5.4%7.2%16.1 $15.71 11/15/20231,290,000 shares $18.80 million +4.9%7.6%17.8 $14.57 10/31/20231,230,000 shares $13.05 million -8.9%7.1%16.9 $10.61 10/15/20231,350,000 shares $14.85 million -12.3%7.8%18.3 $11.00 9/30/20231,540,000 shares $20.90 million +7.7%8.9%21.3 $13.57 9/15/20231,430,000 shares $18.80 million +5.9%8.3%20 $13.15 8/31/20231,350,000 shares $21.45 million +3.9%7.8%15.9 $15.89GENIUS Act: Cancel Your Money? (Ad)They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—not the government—have been handed control of a new class of programmable money. It’s not called a CBDC, but it acts just like one. Your spending could be tracked, limited, or even frozen—whether you opt in or not. Once this system becomes the default, escape won’t be easy.Get the free info kit with 3 ways to protect your money before control kicks in. 8/15/20231,300,000 shares $19.21 million +4.8%7.5%14.6 $14.78 7/31/20231,240,000 shares $21.64 million +2.5%7.3%14.8 $17.45 7/15/20231,210,000 shares $22.08 million +9.0%7.1%13.9 $18.25 6/30/20231,110,000 shares $19.04 million No Change6.5%12.6 $17.15 6/15/20231,110,000 shares $18.76 million +15.4%6.5%12.2 $16.90 5/31/2023961,900 shares $15.63 million +5.3%6.2%12.3 $16.25 5/15/2023913,900 shares $19.27 million -5.3%5.9%12.6 $21.08 4/30/2023965,000 shares $20.24 million +1.4%6.1%13.5 $20.97 4/15/2023951,300 shares $16.07 million +10.2%6.0%10.3 $16.89 3/31/2023862,900 shares $17.40 million -7.4%5.5%8.9 $20.17 3/15/2023932,200 shares $20.49 million -4.4%5.6%9.6 $21.98 2/28/2023974,600 shares $23.95 million +1.5%5.9%7.2 $24.57 2/15/2023960,000 shares $25.32 million -53.2%5.8%6.3 $26.37 1/31/20232,050,000 shares $46.84 million +0.5%12.4%13 $22.85 1/15/20232,040,000 shares $51.10 million +9.1%12.3%15.5 $25.05 12/30/20221,870,000 shares $54.79 million +11.3%11.3%14.9 $29.30 12/15/20221,680,000 shares $43.09 million +33.3%10.3%13.7 $25.65 11/30/20221,260,000 shares $23.74 million -14.3%7.7%12.2 $18.84 11/15/20221,470,000 shares $28.62 million -3.3%9.0%17.2 $19.47 10/31/20221,520,000 shares $29.66 million +0.7%9.1%21 $19.51 10/15/20221,510,000 shares $29.25 million +2.0%9.1%18 $19.37 9/30/20221,480,000 shares $24.54 million -1.3%8.9%14.4 $16.58 9/15/20221,500,000 shares $23.76 million No Change9.0%13.7 $15.84 8/31/20221,500,000 shares $29.75 million -2.6%9.0%14.8 $19.83 8/15/20221,540,000 shares $39.33 million +10.0%9.3%15.1 $25.54 7/31/20221,400,000 shares $31.15 million +45.4%8.2%13.6 $22.25 7/15/2022963,200 shares $17.34 million +7.6%5.7%11 $18.00 6/30/2022895,600 shares $14.00 million +20.5%6.6%13 $15.63 6/15/2022743,100 shares $9.14 million +6.7%5.5%10.4 $12.30 5/31/2022696,300 shares $8.46 million +17.9%5.1%11.1 $12.15 5/15/2022590,600 shares $7.72 million +17.0%4.3%9.4 $13.07 4/30/2022505,000 shares $6.44 million +3.6%3.0%8.7 $12.75 4/15/2022487,500 shares $8.21 million +4.8%2.9%9.2 $16.84 3/31/2022465,200 shares $8.53 million +6.0%2.8%9 $18.33 3/15/2022438,800 shares $5.27 million +7.1%2.7%8.8 $12.00 2/28/2022409,600 shares $4.01 million -3.7%2.5%7.3 $9.78 2/15/2022425,300 shares $4.32 million -0.6%2.6%7.2 $10.15 1/31/2022427,900 shares $5.06 million -0.7%2.6%6.1 $11.82 1/15/2022431,100 shares $4.09 million -3.4%2.5%6.1 $9.49 12/31/2021446,200 shares $5.26 million -0.2%2.6%3.9 $11.79 12/15/2021446,900 shares $5.51 million +17.7%2.6%3.8 $12.34 11/30/2021379,600 shares $5.20 million +4.4%2.2%2.6 $13.71 11/15/2021363,700 shares $6.35 million -3.3%2.1%2.3 $17.46 10/29/2021376,200 shares $5.99 million +13.7%2.2%2.4 $15.93 10/15/2021330,900 shares $4.68 million -70.2%2.0%2.2 $14.13 9/30/20211,110,000 shares $23.29 million +30.7%6.5%9.6 $20.98 9/15/2021849,100 shares $18.31 million +13.5%5.0%6.1 $21.56 8/31/2021747,900 shares $12.78 million +1.7%4.4%6.8 $17.09 8/13/2021735,600 shares $9.20 million No Change4.6%7.6 $12.50 AVTE Short Interest - Frequently Asked Questions What is Aerovate Therapeutics' current short interest? Short interest is the volume of Aerovate Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 4,590,000 shares of AVTE short. 21.72% of Aerovate Therapeutics' shares are currently sold short. Learn More on Aerovate Therapeutics' current short interest. What is a good short interest ratio for Aerovate Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AVTE shares currently have a short interest ratio of 18.0. Learn More on Aerovate Therapeutics's short interest ratio. What is a good short interest percentage for Aerovate Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 21.72% of Aerovate Therapeutics' floating shares are currently sold short. Is Aerovate Therapeutics' short interest increasing or decreasing? Aerovate Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 4,590,000 shares, an increase of 7.0% from the previous total of 4,290,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Aerovate Therapeutics' float size? Aerovate Therapeutics currently has issued a total of 28,985,000 shares. Some of Aerovate Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aerovate Therapeutics currently has a public float of 21,130,000 shares. How does Aerovate Therapeutics' short interest compare to its competitors? 21.72% of Aerovate Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Aerovate Therapeutics: Trevi Therapeutics, Inc. (8.30%), Urogen Pharma (14.85%), Phathom Pharmaceuticals, Inc. (17.04%), Iovance Biotherapeutics, Inc. (24.38%), Immunome, Inc. (17.35%), uniQure N.V. (17.73%), Anavex Life Sciences Corp. (29.54%), Akebia Therapeutics, Inc. (9.36%), Amylyx Pharmaceuticals, Inc. (11.17%), Niagen Bioscience, Inc. (4.29%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Inc ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management Inc. ($3.86 billion), Capital One Financial Corporation ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Corporation ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Aerovate Therapeutics stock? Short selling AVTE is an investing strategy that aims to generate trading profit from Aerovate Therapeutics as its price is falling. AVTE shares are trading down $0.18 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Aerovate Therapeutics? A short squeeze for Aerovate Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AVTE, which in turn drives the price of the stock up even further. How often is Aerovate Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AVTE, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Trevi Therapeutics Short Interest Data Urogen Pharma Short Interest Data Phathom Pharmaceuticals Short Interest Data Iovance Biotherapeutics Short Interest Data Immunome Short Interest Data uniQure Short Interest Data Anavex Life Sciences Short Interest Data Akebia Therapeutics Short Interest Data Amylyx Pharmaceuticals Short Interest Data Niagen Bioscience Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AVTE) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts